CliffBio
small molecule

AZILECT

RASAGILINE MESYLATE

Loss of exclusivityAugust 2027latest FDA-listed patent expiry
CompanyTEVA NEUROSCIENCE INC

Drug detail

Brand nameAZILECT
Active ingredientRASAGILINE MESYLATE
StrengthEQ 0.5MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMay 2006
Marketing statusRX

Listed patents

PatentExpiresType
7815942August 2027substance, product
7572834December 2026product

More from TEVA NEUROSCIENCE INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.